The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 12.469
Citescore: 14.3
All metrics >>
The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
JITC is the official journal of the Society for Immunotherapy of Cancer (SITC). View the SITC 37th Annual Meeting (SITC 2022) Abstracts here.
EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board
Highlighted Articles
Authors
The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.
The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.
Information is also provided on editorial policy, Open Access fees and formatting.
Imaging and Immunotherapy
Review:
Imaging endpoints for clinical trial use: a RECIST perspective
24 November 2022
Review:
Review:
Review:
MRI techniques for immunotherapy monitoring
19 September 2022
Review:
Molecular imaging to support cancer immunotherapy
3 August 2022
Review:
Review:
Review:
Latest Articles
Oncolytic and local immunotherapy:
Clinical/translational cancer immunotherapy:
Immune cell therapies and immune cell engineering:
Review:
Targeting Cbl-b in cancer immunotherapy
7 February 2023
Immunotherapy biomarkers:
Most Read Articles
Case report:
Clinical/translational cancer immunotherapy:
Review:
Immunotherapy biomarkers:
Position article and guidelines:
Altmetrics
What Our Editors Are Reading
In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 35% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2023. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.